TriangleNCT00064337 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 5 years from initial registration, or until death, whichever occurred earlier, on average, about 4.5 years
What was measured
Time from initial registration until death or date of last contact, whichever occurs first, for up to 5 years from the date of the last patient registration.
Analysis population: Eligible and analyzable patients only.
Groups in this outcome
Treatment
MM Induction: dexamethasone 20mg/d PO Days 1-4, 9-12 and 17-20 every 35 days for 2 cycles and thalidomide 200 mg/d PO Days 1-70. Mobilization and SC Collection: MM, MM+AL, MM+LCD: cyclophosphamide 2.5 gm/m2 IV Day 1; mesna 800 mg/m2 IV Day 1 x 3 doses; G-CSF 10 mcg/kg/d SQ Day 2 through day prior to last leukapheresis. Amyloid or LCDD-Only: G-CSF 16 mcg/kg/d SQ Days 1-3 (continued daily until the day prior to the last day of stem cell collection). Conditioning/Transplant - Modified HighDose Melphalan (given for both transplants): melphalan 100 mg/m2/d IV over 20 mins Day -2; PBSC infusion \>/= 3.5 x 10\^6 CD34+ cells/kg IV Day 0. Maintenance (MM only): dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year, followed by dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year. filgrastim cyclophosphamide dexamethasone melphalan thalidomide peripheral blood
| Group | Source count |
|---|---|
| Treatment | 93 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment | 68 | Not reported | 42 | NA | The upper limit of the 95% CI for the median had not yet been reached at time of analysis. |
Complete source fields
- classes
- categories
- measurements
- comment
- The upper limit of the 95% CI for the median had not yet been reached at time of analysis.
- group Id
- OG000
- lower Limit
- 42
- upper Limit
- NA
- value
- 68
- denoms
- counts
- group Id
- OG000
- value
- 93
- units
- Participants
- description
- Time from initial registration until death or date of last contact, whichever occurs first, for up to 5 years from the date of the last patient registration.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- MM Induction: dexamethasone 20mg/d PO Days 1-4, 9-12 and 17-20 every 35 days for 2 cycles and thalidomide 200 mg/d PO Days 1-70. Mobilization and SC Collection: MM, MM+AL, MM+LCD: cyclophosphamide 2.5 gm/m2 IV Day 1; mesna 800 mg/m2 IV Day 1 x 3 doses; G-CSF 10 mcg/kg/d SQ Day 2 through day prior to last leukapheresis. Amyloid or LCDD-Only: G-CSF 16 mcg/kg/d SQ Days 1-3 (continued daily until the day prior to the last day of stem cell collection). Conditioning/Transplant - Modified HighDose Melphalan (given for both transplants): melphalan 100 mg/m2/d IV over 20 mins Day -2; PBSC infusion \>/= 3.5 x 10\^6 CD34+ cells/kg IV Day 0. Maintenance (MM only): dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year, followed by dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year. filgrastim cyclophosphamide dexamethasone melphalan thalidomide peripheral blood
- id
- OG000
- title
- Treatment
- param Type
- MEDIAN
- population Description
- Eligible and analyzable patients only.
- reporting Status
- POSTED
- time Frame
- 5 years from initial registration, or until death, whichever occurred earlier, on average, about 4.5 years
- title
- Overall Survival
- type
- PRIMARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice